ZIP8‐targeted therapies may offer a novel, personalised approach to IDD treatment by modulating inflammation and preserving ECM, potentially enhancing patient outcomes and slowing disease progression. This evidence concerns the gene SLC39A8 and intervertebral disk degenerative disorder.